Concepedia
Statistics
Publications
5
Citations
462
H-Index
Active since
2010
Affiliations
Brigham and Women's Hospital(Current)
KU Leuven
Dana-Farber Cancer Institute
Harvard University
Mark Mayeda is an author at Brigham and Women's Hospital specializing in oncology, molecular oncology, and medicine.
Publications per year
2010–2015
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma
Cheng‐Han Lee, Wen‐Bin Ou, Adrián Mariño‐Enríquez et al. · Proceedings of the National Academy of Sciences · 2012 · 256 citations · Full text
Medicine, Molecular Genetics, Oncology +16
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants
Ellen Weisberg, Hwan Geun Choi, Arghya Ray et al. · Blood · 2010 · 65 citations · Full text
Life Sciences, Medicinal Chemistry, Molecular Biology +17
The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
Tomoko Smyth, Thomas Van Looy, Jayne Curry et al. · Molecular Cancer Therapeutics · 2012 · 59 citations
Medicine, Oncology, Pharmacology +15
<i>CDKN2A</i>/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans
Grant Eilers, Jeffrey T. Czaplinski, Mark Mayeda et al. · Molecular Cancer Therapeutics · 2015 · 53 citations · Full text
Medicine, Dermatology, Oncology +17
Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors
Adrián Mariño‐Enríquez, W-B Ou, Glenn S. Cowley et al. · Oncogene · 2013 · 29 citations · Full text
Medicine, Molecular Biology, Oncology +16
1–5 of 5